Advertisement

International Journal of Hematology

, Volume 76, Issue 2, pp 180–185 | Cite as

Detection of the BCR-ABL Gene by Interphase Fluorescence In Situ Hybridization (iFISH) in Chronic Myelogenous Leukemia Patients after Hemopoietic Stem Cell Transplantation: The Feasibility of iFISH Monitoring of Therapeutic Response in Peripheral Blood

  • You Kyoung Lee
  • Dong Wha Lee
  • Yoo Li Kim
  • Seok Lee
  • Chang Ki Min
  • Yoo-Jin Kim
  • Il-Hoan Oh
  • Tai-Gyu Kim
  • Chun Choo Kim
  • Dong-Wook Kim
Case Report

Abstract

The detection of the Philadelphia (Ph) translocation has been accomplished primarily by cytogenetic analysis and reverse transcriptase polymerase chain reaction (RT-PCR). RT-PCR is highly sensitive (1/104-106) but not quantitatively reliable and is thus unsuitable for the monitoring of Ph-positive cells during therapy. Interphase fluorescence in situ hybridization (iFISH) allows analysis of a large number of cells (>500) in a timely and efficiently quantitative manner. We obtained 118 peripheral blood (PB) and 127 bone marrow (BM) samples from 75 adult chronic myelogenous leukemia (CML) patients undergoing stem cell transplantation. We simultaneously performed nested RT-PCR and iFISH for all samples. False-positive cells were detected in 2.48% ± 0.93% (mean ± SD) of PB samples and 2.75% ± 0.83% of BM samples. The iFISH results for PB and BM ranged from 1.4% to 92.8% and 1.0% to 93.8%, respectively. Correlation analysis of iFISH results for PB versus BM samples showed a strong relation (r = .993). A significant correlation (P < .05) was also found between iFISH and first-round RT-PCR. The sensitivity of BCR-ABL iFISH was similar to that of first-round RT-PCR, and iFISH results for PB and BM were also well correlated. Thus, iFISH analysis of PB and/or BM samples may be more clinically reliable than RT-PCR in the quantitative monitoring of BCR-ABL fusion in CML after transplantation.

Key words

Chronic myelogenous leukemia Interphase FISH BCR-ABL Hemopoietic stem cell transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nowell PC, Hungerford DA. A minute chromosome in human chronic myelocytic leukemia.Science. 1960;132:1497–1501.Google Scholar
  2. 2.
    Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining.Nature. 1973;243:290–293.CrossRefPubMedGoogle Scholar
  3. 3.
    Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.Cell. 1984;36:93–99.CrossRefPubMedGoogle Scholar
  4. 4.
    Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.Nature. 1985;315:550–554.CrossRefPubMedGoogle Scholar
  5. 5.
    Arnoldus EP, Wiegant J, Noordermeer IA, et al. Detection of the Philadelphia chromosome in interphase nuclei.Cytogenet Cell Genet. 1990;54:108–111.CrossRefPubMedGoogle Scholar
  6. 6.
    Tkachuk DC, Westbrook A, Andreeff M, et al. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization.Science. 1990;250:559–562.CrossRefPubMedGoogle Scholar
  7. 7.
    Dewald GW, Schad CR, Christensen ER, et al. The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variants Ph chromosomes in CML and ALL.Cancer Genet Cytogenet. 1993;71:7–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Bentz M, Cabot G, Moos M, et al. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization.Blood. 1994;83:1922–1928.PubMedGoogle Scholar
  9. 9.
    Froncillo MC, Maffei L, Cantonetti M, et al. FISH analysis for CML monitoring?Ann Hematol. 1996;73:113–119.CrossRefPubMedGoogle Scholar
  10. 10.
    Morgan GJ, Hughes T, Janssen JW, et al. Polymerase chain reaction for detection of residual leukemia.Lancet. 1989;1:928–929.CrossRefPubMedGoogle Scholar
  11. 11.
    Sklar J. Polymerase chain reaction: the molecular microscope of residual disease.J Clin Oncol. 1991;9:1521–1524.CrossRefPubMedGoogle Scholar
  12. 12.
    Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.Anal Biochem. 1987;162:156–159.CrossRefPubMedGoogle Scholar
  13. 13.
    Kwok S, Higuchi R. Avoiding false positives with PCR.Nature. 1989;339:237–238.CrossRefPubMedGoogle Scholar
  14. 14.
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement.Lancet. 1986;1:307–310.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lukasova E, Kozubek S, Kozubek M, et al. Localisation and distance between ABL and BCR genes in interphase nuclei of bone marrow cells of control donors and patients with chronic myeloid leukaemia.Hum Genet. 1997;100:525–535.CrossRefPubMedGoogle Scholar
  16. 16.
    Clarkson B, Strife A. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.Leukemia. 1993;7:1683–1721.PubMedGoogle Scholar
  17. 17.
    Morley A. Quantifying leukemia.N Engl J Med. 1998;339:627–629.CrossRefPubMedGoogle Scholar
  18. 18.
    Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.Blood. 1995;86:3118–3122.PubMedGoogle Scholar
  19. 19.
    Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.Blood. 1998;92:3362–3367.PubMedGoogle Scholar
  20. 20.
    Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?Blood. 1999;93:2755–2759.PubMedGoogle Scholar
  21. 21.
    Garcia-Isidoro M, Tabernero MD, Garcia JL, et al. Detection of the Mbcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: comparison with conventional cytogenetics and implications for minimal residual disease detection.Hum Pathol. 1997;28:154–159.CrossRefPubMedGoogle Scholar
  22. 22.
    Muhlmann J, Thaler J, Hilbe W, et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment.Genes Chromosomes Cancer. 1998;21:90–100.CrossRefPubMedGoogle Scholar
  23. 23.
    Yanagi M, Shinjo K, Takeshita A, et al. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells.Leukemia. 1999;13:542–552.CrossRefPubMedGoogle Scholar
  24. 24.
    Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia.Blood. 1998;91:3357–3365.PubMedGoogle Scholar
  25. 25.
    Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridizaton system.Blood. 1997;90:1395–1402.PubMedGoogle Scholar
  26. 26.
    Buno I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald GW. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia.Blood. 1998;92:2315–2321.PubMedGoogle Scholar
  27. 27.
    Dewald GW, Wyatt WA, Silver RT. Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy.Leuk Lymphoma. 1999;34:481–491.CrossRefPubMedGoogle Scholar
  28. 28.
    Mohr B, Bornhauser M, Platzbecker U, et al. Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals.Cancer Genet Cytogenet. 2001;27:111–117.CrossRefGoogle Scholar
  29. 29.
    Mensink E, van de Locht A, Schattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR.Br J Haematol. 1998;102:768–774.CrossRefPubMedGoogle Scholar
  30. 30.
    Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation.Leukemia. 1999;13:1383–1389.CrossRefPubMedGoogle Scholar
  31. 31.
    Chomel JC, Brizard F, Veinstein A, et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferonalpha therapy or allogeneic bone marrow transplantation.Blood. 2000;95:404–408.PubMedGoogle Scholar
  32. 32.
    Le Gouill S, Talmant P, Milpied N, et al. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia.J Clin Oncol. 2000;18:1533–1538.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • You Kyoung Lee
    • 1
  • Dong Wha Lee
    • 1
  • Yoo Li Kim
    • 2
  • Seok Lee
    • 2
  • Chang Ki Min
    • 2
  • Yoo-Jin Kim
    • 2
  • Il-Hoan Oh
    • 2
  • Tai-Gyu Kim
    • 2
  • Chun Choo Kim
    • 2
  • Dong-Wook Kim
    • 2
  1. 1.Department of Clinical Pathology, College of MedicineSoonchunhyang UniversitySeoulKorea
  2. 2.Department of Catholic Hemopoietic Stem Cell Transplantation CenterSt. Mary’s Hospital, The Catholic University of KoreaSeoulKorea

Personalised recommendations